Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for its investigational therapy zilganersen for Alexander disease. The designation follows pivotal data indicating meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results